Phase Ib clinical study of CBP501, cisplatin and nivolumab administered every 3 weeks in patients with advanced refractory tumors. Dose escalation cohort Article

Full Text via DOI: 10.1158/1538-7445.AM2019-CT228 Web of Science: 000488129900204
International Collaboration

Cited authors

  • Matrana, Marc; Tsai, Frank; Satti, Suma; Cleary, James; Estes, Jacob; Khanh Do; Kolmakov, Valentin; Kawabe, Takumi; Shapiro, Geoffrey I.

Publication date

  • 2019

Published in

International Standard Serial Number (ISSN)

  • 0008-5472


  • 79


  • 13